Skip to main content
. 2018 Apr 20;97(16):e0254. doi: 10.1097/MD.0000000000010254

Figure 1.

Figure 1

A: Study flow diagram; B: risk of bias graph and risk of bias summary; C: NT-proBNP comparison between ateroidal MRAs and finerenone. CIs = confidence intervals; MRAs = mineralocorticoid receptor antagonists; NT pro-BNP = N-terminal pro-B-type natriuretic peptide.